|
Diagnostic Tool for High-grade Serous Ovarian Cancer - (HJF 616-21)
Researchers at HJF, Inova Fairfax Hospital (IFH), and the Peter MacCallum Cancer Centre (PMCC) have identified orthogonal protein and transcript-based biomarkers correlating with Homologous Recombination Deficiency (HRD). This may lead to a companion clinical diagnostic assay to prioritize High-Grade Serous Ovarian Cancer (HGSOC) patients for targeted...
Published: 3/14/2025
|
Inventor(s): Nicholas Bateman, Tamara Abulez, Thomas Conrads, George Larry Maxwell, Dale Garsed, David Bowtell, Ahwan Pandey
Keywords(s): Assay, Biomarker Assay, Companion Diagnostic, DDR, DNA Damage Repair, HGSOC, High-Grade Serous Ovarian Carcinoma, Ovarian Cancer, PARP Inhibitors
Category(s): Diagnostics, Therapeutic
|
|
Immunogens and Vaccine Compositions Against Flavivirus - (HJF 624-22)
HJF researchers have developed a novel recombinant flavivirus immunogen that can induce immunogenicity against multiple flaviviruses, including ZIKV (Zika) and DENV (dengue), without life-threatening antibody-dependent enhancement (ADE) responses. Mice immunized with this recombinant immunogen were protected from lethal ZIKV challenge.
Applications...
Published: 3/14/2025
|
Inventor(s): Shelly Krebs, Vincent Dussupt
Keywords(s): Dengue, Flavivirus, Immunogen, Vaccines, Zika
Category(s): Diagnostics, Therapeutic
|
|
DNA Damage Repair Genes in Prostate Cancer - (HJF 557-19)
Prostate cancer patients with DDRG mutations are increasingly considered for targeted cancer therapies. Currently available DDRG mutation tests rely on a rather small number of genes which are not often mutated in African American prostate cancer patients. This invention describes a robust data set on inherited mutations which can be used to develop...
Published: 3/14/2025
|
Inventor(s): Gyorgy Petrovics, Shiv Srivastava
Keywords(s): African American, Caucasian, DDRG, Mutation, Precision Therapy, Prostate Cancer
Category(s): Diagnostics
|
|
Predictive Tool on Probability of Successful Wound Closure - (HJF 637-22)
Greater than 20% of traumatic wound closure attempts fail due to the immuno-molecular status of the healing wound tissue.
Researchers at HJF and the Uniformed Services University for Health Sciences (USU) developed a product that analyzes the individual's wound healing immune response and computes a risk of failure score based on cytokine levels...
Published: 2/24/2025
|
Inventor(s): Seth Schobel-McHugh, Eric Elster, Henry Robertson, Felipe Lisboa, Michael Rouse, Scott Grey
Keywords(s): Biomarker, CDST, Dehisced Wound, Effluent, Healing, Serum, Wound, Wound Closure, Wound Failure
Category(s): Diagnostics, Medical Devices, Therapeutic, Healthcare IT
|
|
ETV1 Monoclonal Antibodies - (HJF 641-23)
ETV1 is a protein of Erythroblast Transformation Specific (ETS) family of transcription factors. Dysregulation of ETV-1 has been observed in many malignancies including, gastrointestinal stromal (GIS), prostatic tumors, and in triple-negative breast cancer.
Researchers at HJF and the Uniformed Services University for the Health Sciences (USU) have...
Published: 2/24/2025
|
Inventor(s): Shyh-Han Tan, Albert Dobi, Shiv Srivastava
Keywords(s): ERG, Monoclonal Antibodies, Prostate Cancer
Category(s): Diagnostics, Research Tool, Therapeutic
|
|
Vaccines Against Fentanyl and Fentanyl Analogs - (HJF 561-19)
A technology related to novel fentanyl hapten compounds and their use in the preparation of vaccines against fentanyl and fentanyl analogs is available for licensing.
Applications and Advantages
Novel compounds for use as vaccines against fentanyl and analogs
High immunogenicity that generates fentanyl specific antibodies to reduce its distribution...
Published: 2/24/2025
|
Inventor(s): Gary Matyas, Oscar Torres, Kenner Rice, Eric Bow, Agnieszka Sulima, Arthur Jacobson
Keywords(s): Antibody, Diagnostics, Fentanyl, Therapeutics, Vaccines
Category(s): Diagnostics, Therapeutic, Vaccine
|
|
Monoclonal Antibodies Against Coronavirus and Their Uses - (HJF 595-21)
Researchers at HJF and the Walter Reed Army Institute of Research (WRAIR) have discovered new human and recombinant monoclonal antibodies (mAbs) that show broad cross reactivity among coronavirus variants with potential applications in diagnostics and therapeutics for coronavirus.
Applications and Advantages
Discovered antibodies can be used in...
Published: 3/14/2025
|
Inventor(s): Shelly Krebs, Kayvon Modjarrad, Nelson Michael, Vincent Dussupt, Gina Donofrio, Samantha Townsley
Keywords(s): Coronavirus, COVID-19, Cross-Reactivity, Monoclonal Antibodies, Respiratory, SARS, SARS-CoV-2, Spike Proteins, Vaccines, Variants
Category(s): Diagnostics, Therapeutic
|
|
Shark Antibodies and Shark-Derived Binding Domains Specific for the SARS-CoV-2 Coronavirus - (HJF 581-20)
HJF scientists have developed a series of single variable domain antibodies (nanobodies or VNARs, derived from nurse sharks) specifically targeting SARS-CoV-2 and other betacoronaviruses, thus providing unique therapeutics and diagnostics for COVID-19 and possibly other betacoronavirus infections.
Applications and Advantages
Fully sequenced, grafted...
Published: 2/24/2025
|
Inventor(s): Michael Gordon Joyce, Kayvon Modjarrad, Helen Dooley
Keywords(s): Antibody, Coronavirus, COVID-19, Diagnostics, Sarbecovirus, SARS-CoV-2, Therapeutics
Category(s): Therapeutic, Diagnostics
|
|
Vaccines against SARS-COV-2 and other Coronaviruses - (HJF 569-20 & HJF 635-22)
Researchers at HJF and the Walter Reed Army Institute of Research (WRAIR) have developed novel vaccines comprised of fusion proteins; Ferritin nanoparticle and antigenic coronavirus peptide(s). These fusion proteins generate simultaneous protective neutralizing immune responses against coronaviruses and their variants.
Applications and Advantages
Innovation...
Published: 3/14/2025
|
Inventor(s): Kayvon Modjarrad, Michael Gordon Joyce
Keywords(s): Coronavirus, COVID-19, Nano-particle, SARS-CoV-2, Self-Assembly, Vaccines, Variants
Category(s): Diagnostics, Therapeutic
|
|
Protein Panels for the Early Diagnosis/Prognosis and Treatment of Aggressive Prostate Cancer - (HJF 528-18)
Prostate cancer is the second most common cancer in men and fourth most common among all cancers. Researchers at HJF in collaboration with researchers at the Pacific Northwest National Laboratory (PNNL) and the National Cancer Institute (NCI) have developed a novel protein-panel based diagnosis or prognosis method that can diagnose and identify if the...
Published: 3/14/2025
|
Inventor(s): Shiv Srivastava, Gyorgy Petrovics, Jennifer Cullen, Tao Liu, Karin Rodland
Keywords(s): Biomarker, Cancer Therapy, Mass Spectrometry (MS), Prostate Cancer, Prostatectomy, Protein Panels, Selected Reaction Monitoring (SRM)
Category(s): Diagnostics, Prognostic
|
